Our talented team of scientists, determined to do their part to contribute to the fight against the worst healthcare disaster in 100 years, had a brilliant idea to repurpose a legacy compound, RLF-100TM (aviptadil), a recombinant form of a naturally occurring peptide found in the lung - Vasoactive Intestinal Peptide (VIP) - to protect the lung from injury due to COVID-19. Taking advantage of the extraordinary measures implemented in the U.S. to speed up clinical research for COVID-19 therapeutics, Relief partnered with NeuroRx Inc., a U.S. based biotech that excels at innovative novel therapeutic development for rapid deployment. Ten weeks from concept to clinic, we began our journey to providing this potentially life-saving drug to critical COVID-19 patients.
Preparing for U.S. Commercialization
Relief and NeuroRx have also taken steps to increase manufacturing of RLF-100™ to prepare for commercialization in case of FDA approval. The companies have contracted with Nephron Pharmaceuticals, Inc. to manufacture, fill & finish, commercial supplies of RLF-100™ in order to ensure that adequate drug inventory will be immediately available. Similarly, they have contracted with Bachem Americas to manufacture sufficient RLF-100™ drug substance to treat 1 million patients. Bachem was the first peptide manufacturer to synthesize RLF-100™ and has played a leading role in the development of the drug substance over the past 20 years. An additional contract was established with a leading nationwide pharmaceutical logistics partner to ensure overnight supply to U.S. hospitals.